Search Results - "Goss, Paul"

Breast cancer in China by Fan, Lei, MD, Strasser-Weippl, Kathrin, MD, Li, Jun-Jie, MD, St Louis, Jessica, BA, Finkelstein, Dianne M, Prof, Yu, Ke-Da, MD, Chen, Wan-Qing, MD, Shao, Zhi-Ming, MD, Goss, Paul E, Prof

“…Summary The health burden of cancer is increasing in China, with more than 1·6 million people being diagnosed and 1·2 million people dying of the disease each…”
Get full text

Does tumour dormancy offer a therapeutic target? by Chambers, Ann F, Goss, Paul E

“…The increasing number of cancer survivors has highlighted the problem of tumour dormancy, which can lead to relapse. Preclinical models and initial clinical…”
Get full text

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population by Sgroi, Dennis C, Prof, Sestak, Ivana, PhD, Cuzick, Jack, Prof, Zhang, Yi, PhD, Schnabel, Catherine A, PhD, Schroeder, Brock, PhD, Erlander, Mark G, PhD, Dunbier, Anita, PhD, Sidhu, Kally, BSc, Lopez-Knowles, Elena, PhD, Goss, Paul E, Prof, Dowsett, Mitch, Prof

“…Summary Background Biomarkers to improve the risk–benefit of extended adjuvant endocrine therapy for late recurrence in patients with…”
Get full text

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years by Goss, Paul E, Ingle, James N, Pritchard, Kathleen I, Robert, Nicholas J, Muss, Hyman, Gralow, Julie, Gelmon, Karen, Whelan, Tim, Strasser-Weippl, Kathrin, Rubin, Sheldon, Sturtz, Keren, Wolff, Antonio C, Winer, Eric, Hudis, Clifford, Stopeck, Alison, Beck, J. Thaddeus, Kaur, Judith S, Whelan, Kate, Tu, Dongsheng, Parulekar, Wendy R

“…An additional 5 years of adjuvant aromatase-inhibitor therapy in women with early hormone-receptor–positive breast cancer resulted in longer disease-free…”
Get full text

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer by Isakoff, Steven J, Mayer, Erica L, He, Lei, Traina, Tiffany A, Carey, Lisa A, Krag, Karen J, Rugo, Hope S, Liu, Minetta C, Stearns, Vered, Come, Steven E, Timms, Kirsten M, Hartman, Anne-Renee, Borger, Darrel R, Finkelstein, Dianne M, Garber, Judy E, Ryan, Paula D, Winer, Eric P, Goss, Paul E, Ellisen, Leif W

“…The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is of…”
Get full text

Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover by Jin, Huan, Tu, Dongsheng, Zhao, Naiqing, Shepherd, Lois E, Goss, Paul E

“…The interim analysis of the National Cancer Institute of Canada Clinical Trials Group MA.17 trial showed that letrozole was significantly better than placebo…”
Get full text

Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes by Jindal, Sonali, Pennock, Nathan D., Sun, Duanchen, Horton, Wesley, Ozaki, Michelle K., Narasimhan, Jayasri, Bartlett, Alexandra Q., Weinmann, Sheila, Goss, Paul E., Borges, Virginia F., Xia, Zheng, Schedin, Pepper

“…Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as…”
Get full text

Exemestane for Breast-Cancer Prevention in Postmenopausal Women by Goss, Paul E, Ingle, James N, Alés-Martínez, José E, Cheung, Angela M, Chlebowski, Rowan T, Wactawski-Wende, Jean, McTiernan, Anne, Robbins, John, Johnson, Karen C, Martin, Lisa W, Winquist, Eric, Sarto, Gloria E, Garber, Judy E, Fabian, Carol J, Pujol, Pascal, Maunsell, Elizabeth, Farmer, Patricia, Gelmon, Karen A, Tu, Dongsheng, Richardson, Harriet

“…In postmenopausal women at increased risk for breast cancer, exemestane reduced the annual incidence of invasive breast cancer by 65% after a median follow-up…”
Get full text

Epidemiology and pathophysiology of pregnancy-associated breast cancer: A review by Ruiz, Rossana, Herrero, Carmen, Strasser-Weippl, Kathrin, Touya, Diego, St. Louis, Jessica, Bukowski, Alexandra, Goss, Paul E.

“…The interactions between pregnancy and breast cancer (BC) are complex. Overall, parity is associated with long-term protective effects against BC, however in a…”
Get full text

Current Status and Future Projections of Breast Cancer in Asia by Fan, Lei, Goss, Paul E., Strasser-Weippl, Kathrin

“…Asia is the world's largest continent comprising about 3/5 of the human population. Breast cancer is the most common type of cancer and the second leading…”
Get full text

Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker by SGROI, Dennis C, CARNEY, Erin, SCHNABEL, Catherine A, ERLANDER, Mark G, INGLE, James N, PORTER, Peggy, MUSS, Hyman B, PRITCHARD, Katherine I, DONGSHENG TU, RIMM, David L, GOSS, Paul E, ZARRELLA, Elizabeth, STEFFEL, Lauren, BINNS, Shemeica N, FINKELSTEIN, Dianne M, SZYMONIFKA, Jackie, BHAN, Atul K, SHEPHERD, Lois E, YI ZHANG

“…Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)-positive breast cancer are limited. The HOXB13/IL17BR (H/I)…”
Get full text

Breast cancer in Mexico: a growing challenge to health and the health system by Chávarri-Guerra, Yanin, MD, Villarreal-Garza, Cynthia, MD, Liedke, Pedro ER, MD, Knaul, Felicia, PhD, Mohar, Alejandro, Prof, Finkelstein, Dianne M, Prof, Goss, Paul E, Prof

“…Summary Breast cancer is a major public health issue in low-income and middle-income countries. In Mexico, incidence and mortality of breast cancer have risen…”
Get full text

Lapatinib: Current Status and Future Directions in Breast Cancer by Moy, Beverly, Goss, Paul E.

“…Lapatinib is an oral receptor tyrosine kinase inhibitor, targeting both the ErbB‐1 and ErbB‐2 receptors. Pre‐clinical in vitro and in vivo models indicate that…”
Get full text

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial by GOSS, Paul E, INGLE, James N, D'SOUZA, David P, CHALCHAL, Haji, SPADAFORA, Silvana, STEARNS, Vered, PEREZ, Edith A, LIEDKE, Pedro E. R, LANG, Istvan, ELLIOTT, Catherine, GELMON, Karen A, CHAPMAN, Judy-Anne W, PRITCHARD, Kathleen I, SHEPHERD, Lois E, ELLIS, Matthew J, SLEDGE, George W, BUDD, G. Thomas, RABAGLIO, Manuela, ANSARI, Rafat H, JOHNSON, David B, TOZER, Richard

“…In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors…”
Get full text

The Emerging Role of the Insulin‐Like Growth Factor Pathway as a Therapeutic Target in Cancer by Ryan, Paula D., Goss, Paul E.

“…Learning Objectives After completing this course, the reader will be able to: Discuss the characteristics of the IGF system including its endocrine as well as…”
Get full text

Breast cancer in Brazil: present status and future goals by Lee, Brittany L, MD, Liedke, Pedro ER, MD, Barrios, Carlos H, Prof, Simon, Sergio D, Prof, Finkelstein, Dianne M, Prof, Goss, Paul E, Prof

“…Summary Breast cancer is the most common cancer in women worldwide and 70% of breast cancer deaths occur in women from low-income and middle-income countries…”
Get full text

Aromatase Inhibitors and Bone Health in Women With Breast Cancer by CHIEN, Amy Jo, GOSS, Paul E

Get full text

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial by Goss, Paul E, Prof, Smith, Ian E, Prof, O'Shaughnessy, Joyce, MD, Ejlertsen, Bent, Prof, Kaufmann, Manfred, Prof, Boyle, Frances, MBBS, Buzdar, Aman U, Prof, Fumoleau, Pierre, Prof, Gradishar, William, Prof, Martin, Miguel, Prof, Moy, Beverly, MD, Piccart-Gebhart, Martine, MD, Pritchard, Kathleen I, Prof, Lindquist, Deborah, MD, Chavarri-Guerra, Yanin, MD, Aktan, Gursel, MD, Rappold, Erica, BSN, Williams, Lisa S, MSc, Finkelstein, Dianne M, Prof

“…Summary Background Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab—the standard adjuvant treatment. We…”
Get full text

Lapatinib‐Associated Toxicity and Practical Management Recommendations by Moy, Beverly, Goss, Paul E.

“…Learning Objectives After completing this course, the reader will be able to: Discuss lapatinib‐associated toxicities and provide practical management…”
Get full text

Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review by Froes Brandao, Denise, Strasser‐Weippl, Kathrin, Goss, Paul E.

“…Hyperprolactinemia, defined as a sustained elevation of prolactin (PRL) levels greater than 530 mIU/L in women and greater than 424 mIU/L in men, has been…”
Get full text